Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
521-540 of 998 trials

Prolonged Seizures: Staccato Alprazolam Study

We are investigating whether Staccato Alprazolam is safe and effective for quickly stopping prolonged seizures in individuals aged 12 and older. The study compares its effects to a placebo to assess its benefits.

Prolonged Seizure3-6 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurology

Diffuse Large B-Cell Lymphoma: Epcoritamab Plus Lenalidomide

We are studying whether a new combination of epcoritamab and lenalidomide can improve survival rates for adults with relapsed or refractory diffuse large B-cell lymphoma compared to standard treatments.

Relapsed or Refractory Diffuse Large B-Cell Lymphoma6-12 monthsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Gastric Cancer: New Drug Combinations

We are studying new combinations of medications alongside chemotherapy for people with advanced gastric or gastroesophageal junction cancer. The goal is to see if these combinations improve treatment outcomes and safety.

Gastric AdenocarcinomaEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

The LIFE-MET Study: Metformin and Lifestyle Changes in Early Puberty

We are investigating how Metformin and lifestyle interventions may influence growth and development in girls with overweight and early puberty. The study looks at changes in body composition and pubertal progression.

Precocious Puberty and Overweight1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteEndocrinologyPediatrics

Chronic Kidney Disease: BI 690517 with Empagliflozin

We are studying whether a new daily pill can help prevent worsening kidney disease and heart problems in people with chronic kidney disease. Participants will compare this treatment to a placebo to see its effects.

Chronic Kidney Disease>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyNephrology

Advanced Prostate Cancer: Debio 4228 Study

We are testing a new medication, Debio 4228, to see if it effectively lowers hormone levels in men with advanced prostate cancer. The study will also look at how well the medication is tolerated and its safety profile.

Advanced Prostate Cancer6-12 monthsEfficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

B-Cell Blood Cancers: AZD5492 Treatment Study

We are investigating whether AZD5492 is safe and effective for adults with relapsed or refractory B-cell malignancies, both on its own and with other cancer treatments.

B-Cell Malignancies>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Calcium Absorption: Glycocholate and Butyrate Study

We are testing the safety and tolerability of glycocholate and butyrate in healthy women who have undergone Roux-en-Y gastric bypass. This study aims to see if these substances can help improve calcium absorption.

Postoperative Obesity≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyGastroenterology

Crizotinib Safety Study for Cancer Patients

We are monitoring the safety of crizotinib for individuals who have participated in earlier studies. This research aims to ensure the continued well-being of patients using this treatment.

Solid TumorMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Multiple Myeloma: Anitocabtagene Autoleucel Study

We are comparing a new treatment called anitocabtagene autoleucel with standard therapies for patients with relapsed or refractory multiple myeloma. The goal is to see which option works better and is safer for patients.

Relapsed/Refractory Multiple MyelomaConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

HIV Treatment: Combination Therapy Study

We are investigating a combination of three drugs to see if they can help reactivate HIV in people living with the virus. This study aims to understand the safety and effectiveness of these treatments.

HIV-1≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal Medicine

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy: ION-682884 Study

We are assessing the long-term safety and effectiveness of ION-682884 in patients with hereditary transthyretin-mediated amyloid polyneuropathy. This study aims to understand how well the treatment works over time.

Familial Amyloid PolyneuropathyConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Celiac Disease: Amlitelimab Treatment Study

We are investigating whether amlitelimab can help adults with non-responsive celiac disease improve their symptoms and intestinal health while on a gluten-free diet. The study also examines the safety of this new treatment.

Coeliac Disease6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Parkinson’s Disease and Multiple System Atrophy: Exidavnemab Study

We are testing the safety and tolerability of a new treatment called exidavnemab in patients with Parkinson’s disease and Multiple System Atrophy. This study will help us understand how well different doses are accepted by patients.

Parkinson's DiseaseMultiple System Atrophy6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteNeurology

THEO-260 for Ovarian Cancer Treatment

We are studying a new treatment for patients with high-grade serous or endometrioid ovarian cancer to see if it is safe and effective. This trial will help us understand the best dose and how well it works compared to existing options.

Ovarian Cancer>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Non-Small Cell Lung Cancer: Alectinib and Chemotherapy Study

We are investigating how well alectinib combined with chemotherapy works for patients with early-stage non-small cell lung cancer. This study focuses on those whose cancer can be surgically removed and who have specific biomarker characteristics.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Atopic Dermatitis: APG777 Treatment Study

We are studying a new treatment called APG777 for people with moderate-to-severe atopic dermatitis. The goal is to see if it helps reduce symptoms like itching and skin pain compared to a placebo.

Atopic Dermatitis>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Blood Cancer: Long-term Study of Zanubrutinib

We are evaluating the long-term safety and effectiveness of Zanubrutinib in patients with B-cell malignancies. This study is for those who have previously participated in a related trial.

B-cell Lymphoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Refractory Invasive Pulmonary Aspergillosis: Nebulized PC945

We are studying a new nebulized treatment, PC945, for patients with a tough-to-treat fungal infection. The goal is to see if it works better when combined with standard antifungal therapies.

Pulmonary Aspergillosis3-6 monthsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPulmonology

Cholestatic Pruritus: Maralixibat Study

We are testing a new medication, maralixibat, for individuals with cholestatic pruritus to see if it can reduce itching and lower bile acid levels in the blood.

Cholestatic PruritusConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesPartially RemoteDermatologyHepatology